Results 81 to 90 of about 1,567,257 (239)

Nail Toxicities Associated With Anticancer Therapies in Children

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Nail toxicities are a frequent yet often underrecognized component of dermatologic adverse events in children receiving anticancer therapies. Both conventional cytotoxic chemotherapy and newer targeted agents can affect the nail matrix, nail bed and periungual tissues, producing a broad spectrum of clinical manifestations that range from ...
Luca Rapparini, Michela Starace
wiley   +1 more source

The FGF/FGFR System in the Biology and Therapeutic Landscape of Pediatric CNS Tumors

open access: yesMedicinal Research Reviews, EarlyView.
ABSTRACT Central nervous system (CNS) tumors are the most common solid malignancies in children, comprising a highly heterogeneous group of neoplasms defined by distinct molecular alterations and clinical behaviors. Advances in molecular genetics have underscored the relevance of specific signaling pathways in driving pediatric tumorigenesis, among ...
Serena Filiberti   +6 more
wiley   +1 more source

Cutaneous neurofibromas in Neurofibromatosis type I: a quantitative natural history study

open access: yesOrphanet Journal of Rare Diseases, 2018
BackgroundNeurofibromatosis type 1 (NF1) is a genetic disorder characterized by a predisposition to develop multiple benign tumors. A major feature of NF1 is the development of localized cutaneous neurofibromas.
Ashley Cannon   +6 more
semanticscholar   +1 more source

Prime editing in neuropsychiatric disorders: From mutation‐specific target selection to clinical translation

open access: yesNeuroprotection, EarlyView.
Abstract Prime editing, a novel clustered regularly interspaced short palindromic repeats (CRISPR)‐based technology, fuses a reverse transcriptase (RT) to an engineered CRISPR‐associated protein 9 (Cas9) and uses a prime editing guide RNA (pegRNA)‐encoded template.
Tianshan Ji   +4 more
wiley   +1 more source

NEUROFIBROMATOSIS TIPO I DIAGNOSTICADA EN EL EMBARAZO

open access: yesRevista Chilena de Obstetricia y Ginecología, 2004
Se presenta un caso clínico de neurofibromatosis tipo I diagnosticada a las 28 semanas de embarazo con evolución materna y fetal satisfactoriaA clinical case of neurofibromatosis type I is presented with diagnosis at 28 weeks of pregnancy with ...
René Rivera Z   +3 more
doaj  

Neurofibromatosis type 1 or Von Recklinghausen's disease. A case report

open access: yesMedisur, 2023
Neurofibromatosis type I or Von Recklinghausen's disease is one of the genetic diseases that affect the nervous system, named for its common embryonic origin.
Marisleidy Denis Rodríguez   +3 more
doaj  

Audiological Characteristics in Vestibular Schwannoma Patients

open access: yesWorld Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT Objective Vestibular schwannoma (VS) is a benign tumor that originates from the Schwann cells of the vestibular nerve sheath in the internal auditory canal. This retrospective study collected data from patients with VS who underwent surgical treatment to identify their demographic characteristics and audiometric features.
Shan Zeng   +4 more
wiley   +1 more source

The coexistence of neurofibromatosis type I and celiac disease in a child

open access: yesThe Turkish Journal of Gastroenterology, 2018
Cite this article as: Işık İA, Akbulut UE. The coexistence of neurofibromatosis type I and celiac disease in a child. Turk J Gastroenterol 2018; 29: 522-3.
İshak Abdurrahman Işık   +1 more
doaj   +1 more source

Transoral Robotic Resection of Glossopharyngeal Neurofibroma: A Case Report

open access: yesWorld Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT This case highlights the diagnostic challenges posed by rare oropharyngeal neurofibromas, their potential to mimic other conditions, and the novel application of transoral robotic surgery (TORS) for the management of an oropharyngeal neurofibroma. A 47‐year‐old female presented with a 1‐year history of a left tonsillar mass.
Cody L. Messick   +7 more
wiley   +1 more source

Targeting KRAS for cancer therapy

open access: yesBritish Journal of Pharmacology, EarlyView.
In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy